181 related articles for article (PubMed ID: 37990105)
1. EMT-related gene risk model establishment for prognosis and drug treatment efficiency prediction in hepatocellular carcinoma.
Gao X; Yang C; Li H; Shao L; Wang M; Su R
Sci Rep; 2023 Nov; 13(1):20380. PubMed ID: 37990105
[TBL] [Abstract][Full Text] [Related]
2. An epithelial-mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma.
Zhang Y; Li Y; Zuo Z; Li T; An Y; Zhang W
Pathol Oncol Res; 2023; 29():1611016. PubMed ID: 36910014
[No Abstract] [Full Text] [Related]
3. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
[TBL] [Abstract][Full Text] [Related]
4. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma.
Liu Z; Wang J; Li S; Li L; Li L; Li D; Guo H; Gao D; Liu S; Ruan C; Dang X
Front Immunol; 2022; 13():1076045. PubMed ID: 36591279
[TBL] [Abstract][Full Text] [Related]
5. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients.
Wang J; Han K; Zhang C; Chen X; Li Y; Zhu L; Luo T
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33988674
[TBL] [Abstract][Full Text] [Related]
7. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of epithelial mesenchymal transition-related prognostic model for hepatocellular carcinoma.
Wang X; Xing Z; Xu H; Yang H; Xing T
Aging (Albany NY); 2021 Apr; 13(10):13822-13845. PubMed ID: 33929972
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
10. A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients.
Liu T; Chen X; Peng B; Liang C; Zhang H; Wang S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10255-10267. PubMed ID: 37269346
[TBL] [Abstract][Full Text] [Related]
11. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
Li X; Lin J; Pan Y; Cui P; Xia J
Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
[No Abstract] [Full Text] [Related]
14. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients.
Lv W; Yao Q
Dis Markers; 2022; 2022():9428660. PubMed ID: 35069936
[TBL] [Abstract][Full Text] [Related]
15. Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.
Dai K; Liu C; Guan G; Cai J; Wu L
BMC Cancer; 2022 May; 22(1):496. PubMed ID: 35513781
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
Chen S; Zhao E
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631
[TBL] [Abstract][Full Text] [Related]
17. [Construction of a prognostic model for hepatocellular carcinoma based on pyroptosis-related genes].
Rong HC; Zhao WF; Zheng N; Guo ZH; Wang YW; Huang XP
Zhonghua Gan Zang Bing Za Zhi; 2023 May; 31(5):509-517. PubMed ID: 37365028
[No Abstract] [Full Text] [Related]
18. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
19. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma.
Huo J; Wu L; Zang Y
J Cell Mol Med; 2021 Jan; 25(2):1151-1165. PubMed ID: 33300278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]